(Q42448542)

31 October 2017

title

Dipyridamole inhibits PDGF- and bFGF-induced vascular smooth muscle cell proliferation (English)

1 reference

31 October 2017

Himmelfarb J

1

1 reference

31 October 2017

Couper L

series ordinal

2

1 reference

31 October 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

31 October 2017

1 reference

31 October 2017

volume

52

1 reference

31 October 2017

issue

6

1 reference

31 October 2017

page(s)

1671-1677

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.1997.501

31 October 2017

exact match

0 references

cites work

Hemodialysis vascular access morbidity in the United States.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Pharmacomechanical thrombolysis and angioplasty in the management of clotted hemodialysis grafts: early and late clinical results

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Permanent vascular access: a nephrologist's view

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Role of basic fibroblast growth factor in vascular lesion formation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

The effect of dipyridamole on platelet function: correlation with blood levels in man.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Reduction of intimal thickening in canine coronary bypass vein grafts with dipyridamole and aspirin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: implications in the treatment of restenosis after angioplasty

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

https://api.crossref.org/works/10.1038%2FKI.1997.501

1 reference

7 January 2021

https://api.crossref.org/works/10.1038%2FKI.1997.501

1 reference

7 January 2021

Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenicity following injury: influence of salicylate and dipyridamole treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Mode of action of dipyridamole on human platelets

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

The human pharmacology of platelet inhibition: pharmacokinetics relevant to drug action

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Dipyridamole and vascular prostacyclin production

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosine

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Inhibitors of "spontaneous" platelet aggregation in whole blood.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Effect of dipyridamole on human platelet behaviour.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Effect of Dipyridamole and Two Pyrimido-Pyrimidine Derivatives on the Kinetics of Human Platelet Aggregation and on Platelet Adhesiveness

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Model system to study interaction of platelets with damaged arterial wall. II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719

1 reference

https://api.crossref.org/works/10.1038%2FKI.1997.501

7 January 2021

Identifiers

DOI

10.1038/KI.1997.501

1 reference

31 October 2017

1 reference